Aplastic anaemia (AA) is a life-threatening hematopoietic disorder characterized by hypoplasia and pancytopenia with increasing fat cells in the bone marrow (BM). The BM-derived mesenchymal stem cells (MSCs) from AA are more susceptible to be induced into adipogenic differentiation compared with that from control, which may be causatively associated with the fatty BM and defective hematopoiesis of AA.
| INTRODUCTION
Aplastic anaemia (AA) is a rare and life-threatening hematopoietic disorder characterized by hypoplasia and pancytopenia with fatty bone marrow (BM). 1 The pathogenic factors causally associated with AA may include immune abnormality, quantitative and qualitative defects in hematopoietic stem/progenitors cells and altered marrow microenvironment. 2, 3 Bone marrow mesenchymal stem cells (MSCs) can differentiate into osteoblast, adipocytes and chondrocytes, which together constitute the major cellular components of BM microenvironment providing critical support for hematopoiesis. 4 There is increasing evidences that BM-MSCs derived from AA patients display decreased proliferation, aberrant morphology, altered transcriptome profile and impaired differentiation. [5] [6] [7] Aplastic anaemiaderived bone marrow mesenchymal stem cells are more susceptible to be induced to differentiate into adipocyte at the expense of osteoblast, 8 which, to some degree, may explain the fatty phenomenon in AA BM and defects in hematopoietic support. Despite considerable progress, the role of BM-MSCs-mediated microenvironment changes in AA pathogenesis and the molecular mechanism of AA MSCs prone to adipogenic lineage remain to be determined.
Standard front line treatment for AA is either immunosuppressive therapy (IST) or hematopoietic stem cell transplantation (HSCT), which is often accompanied by incomplete recovery, relapse and transplant-related complications, such as chronic or acute graft-vshost-diseases (GVHD). 9, 10 Developing new therapeutic strategy for AA is of great significance. Levamisole was originally designed for antihelminthic applications in 1971 and has subsequently been reported to have a broad range of immunomodulatory effects. 11, 12 Li et al 13 first conducted a prospective trial to treat moderate AA patients by a novel immunosuppressive strategy of cyclosporine alternatively combined with levamisole and achieved encouraging results. However, the molecular mechanism is not clear.
Here in this study, we used levamisole to treat AA BM-MSCs in vitro and found that levamisole could significantly suppress adi- 
| MATERIALS AND METHODS

| Cell culture
Mesenchymal stem cells were isolated from the BM of AA patients and healthy controls and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal bovine serum (FBS; Gibco). Seven AA patients (4 males and 3 females aged 16-68) and 6 controls (3 male and 3 female aged 27-56) were enrolled in this study. The AA patients were diagnosed according to the guidelines previously reported. 14 All the human samples were obtained from 
| Adipogenic induction and levamisole treatment
Adipogenic differentiation was performed according to the method described elsewhere with minor modifications. 15 The MSCs were seeded into 12-well plates. Upon reaching confluence, the MSCs were changed into adipogenic medium (AM) composed of DMEM with 10% FBS, 1 μmol/L dexamethasone, 0.01 mg/mL insulin, 100 μg/mL indomethacin and 0.5 mmol/L 3-isobutyl-1-methylxanthine for 14 days (all purchased from Sigma, St. Louis, MO, USA).
Levamisole (Sigma) treatment was performed by adding levamisole into the AM at final concentration of 150 μg/mL.
| Oil red O staining
The cells were rinsed with PBS twice in the plates after discarding the supernatant and fixed with 4% paraformaldehyde at room temperature for 20 minutes. The cells were then washed with PBS and stained with oil red O (Solarbio) for 20 minutes followed by washing with PBS. Lipid droplets were observed and photographed using an IX71 Olympus microscope (Olympus, Tokyo, Japan). Quantification of the staining was performed using Image-Pro Plus 6.0 software.
| RNA extraction and qRT-PCR analysis
Total RNA was extracted from cell samples using TRIzol Reagent (Invitrogen) and quantified using the NanoDrop 2000 spectrophotometer (Thermo Scientific, Bremen, Germany). The first strand of cDNA was synthesized using M-MLV reverse transcriptase (Invitrogen) according to the manufacturer's instructions. Oligo (dT) was used as the primer for reverse transcription of mRNAs. qRT-PCR was performed in a Bio-Rad CFX-96 System (Bio-Rad, Foster City, CA, USA) using the SYBR Premix (CWBio). The primers used for reverse transcription and qRT-PCR were listed in Table S1 .
| Plasmid construction
The ZFP36L1 cDNA was amplified and cloned into pmiRNA1 (System Biosciences, SBI, CA, USA) and pcDNA6 (Invitrogen) to get its expression plasmids. The fragment of PPARGC1B 3′ untranlated regions (UTR) was inserted into modified pcDNA6-GFP plasmid (Invitrogen). The shRNA sequences for ZFP36L1 and nontarget control were synthesized, annealed and inserted into pll3.7 (Addgene).
The shRNA sequences for PPARGC1B were synthesized, annealed and inserted into pSIH-H1 (System Biosciences, SBI). The primers LIU ET AL.
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and oligonucleotides used for plasmid construction were listed in Table S2 .
| Lentivirus production and cell infection
The recombination lentiviruses for over-expression and knockdown were produced using the pmiRNA1-and pll3.7/pSIH-H1-based constructs. Lentivirus packaging was performed using the 
| GFP reporter assay
Two hundred and ninety-three TN cells were cotransfected with pcDNA6-GFP-PPARGC1B (or pcDNA6-GFP) and pcDNA6-ZFP36L1 
| Statistical analysis
Student's t test (2-tailed) was performed to analyse the data. Statistical significance was set at P < .05, as indicated by an asterisk (*P < .05; **P < .01). The result obtained is also consistent with the previous literatures, 8 and to some extent, explained the fatty phenomenon of AA marrow.
| RESULTS
| AA BM-MSCs exhibits increased adipogenic capacity relative to control BM-MSCs
| Levamisole inhibits the adipogenic differentiation of AA BM-MSCs
To seek a promising drug candidate which may be used to inhibit adipogenesis and improve BM microenvironment of AA, we tested a series of small molecules using the in vitro adipogenic differenti- F I G U R E 1 BM-MSCs derived from AA patients have increased adipogenic capacity relative to that from health controls. The 3rd passage BM-MSCs derived from AA patients and controls were incubated with adipogenic medium for 14 d. A, The cells were stained with oil red O and presented in the left, and the relative quantification of the staining was analysed and shown in the right. B, Adipogenic markers including PPARγ, PLIN1, LPL and FABP4 were detected using qRT-PCR. Actin was used as a loading control. *P < .05 and **P < .01, Student's t test. AA, aplastic anaemia; BM, bone marrow; MSCs, mesenchymal stem cells
| ZFP36L1 shows increased expression upon levamisole treatment and acts as a negative regulator of adipogenic differentiation
To reveal the underlying mechanism of levamisole in suppressing adipogenic differentiation of AA BM-MSCs, we first consulted the gene expression profiles of adipogenic differentiation and AA patients published before [16] [17] [18] | 4499 presence of ZFP36L1 resulted in less formation of droplets (Figure 4F) . Collectively, these results suggested ZFP36L1's function as an important negative regulator in adipogenic differentiation of AA BM-MSCs.
| PPARGC1B mRNA is identified as a direct target of ZFP36L1
ZFP36L1 is a RNA binding protein that mainly binds to the adenineuridine-rich elements (AREs) in the 3′-UTRs and promotes the decay of the target RNAs. 19 To search for downstream targets of ZFP36L1, we first consulted the AREsite (http://nibiru.tbi.univie.ac.at/AREsite 2/welcome) 20 and downloaded the mRNAs bearing UUAUUUAUU motif in their 3′UTRs, which is implicated by previous work that ZFP36L2, a ZFP36L1 homolog, binds to UUAUUUAUU motif with priority. 21 There are 1393 mRNAs containing UUAUUUAUU motif.
We first focused LPL and PPARGC1B that have been reported to be associated with adipogenesis. 22 binding motif were cloned into pcDNA6-GFP for GFP reporter assay, as depicted in Figure 5D . The GFP expression was presented as fluorescence pictures and flow cytometry analysis ( Figure 5E,F) , which demonstrated that ZFP36L1 negatively regulates GFP expression in PPARGC1B-3′UTR-dependant manner. Similar results were not observed in LPL-3′UTR-GFP reporter assay ( Figure S1 ), implying that LPL may not be a direct target of ZFP36L1.
| Knockdown of PPARGC1B impairs adipogenic differentiation of AA BM-MSCs
PPARGC1B was originally identified by virtue of its function to stimulate the activity of several transcription factors and nuclear receptors. 24 To investigate the effect of PPARGC1B on adipogenic differentiation, we make use of the recombined lentivirus that express specific short hairpin RNA for PPARGC1B (lentishPPARGC1B) to infect AA BM-MSCs followed by adipogenic induction for 14 days. qRT-PCR analysis revealed that lenti-shPPARGC1B infection significantly decreased PPARGC1B mRNA expression ( Figure 6A ), which resulted in significant down-regulation of the mRNA levels of the adipogenic differentiation markers (PPARγ, PLIN1, LPL and FABP4; Figure 6B ) as compared with the lenti-ctrl F I G U R E 5 PPARGC1B mRNA is verified as a direct target of ZFP36L1. A, PPARGC1B expression was detected using qRT-PCR during the adipogenic differentiation with and without levamisole treatment. B-C, The mRNA level of ZFP36L1 and PPARGC1B was determined in AA BM-MSCs infected with lenti-shZFP36L1 (or lenti-ctrl) and lenti-ZFP36L1 (or lenti-ctrl), respectively. D, Schematic outline of PPARGC1B-GFP reporter construct. E-F, GFP reporter assay. 293TN cells were co-transfected with each pcDNA6-GFP-based constructs (pcDNA6-GFP and PPARGC1B) and pcDNA6-ZFP36L1 (or pcDNA6). The relative GFP expression was presented as fluorescence pictures (E) and also analysed by flow cytometry (F). **P < .01, Student's t test. AA, aplastic anaemia; BM, bone marrow; MSCs, mesenchymal stem cells; PPARGC1B, peroxisome proliferator-activated receptor gamma coactivator 1 beta belongs to the zinc finger protein family and has been implicated to bind AREs in the 3′UTRs of mRNAs through its RNA binding domain, resulting in destabilization of the target RNAs. 37 As a post-transcriptional regulator, ZFP36L1 has been reported to participate in erythroid differentiation and monocyte/macrophage differentiation by directly targeting stat5b and CDK6 expression, 38, 39 respectively. ZFP36L1 can also act as a tumour suppressor to influence tumorigenesis through negatively regulating VEGFA and Bcl2 expression. 40, 41 However, the role of ZFP36L1 in adipogenesis has only been implicated by the report that it could enhance the degradation of PPARγ2 mRNA transcript in 3T3-L1 preadipocytes. 42 In this study, through lentiviruses-mediated ZFP36L1 over-expres- 
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